Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gstm2-ps1 siRNA
- Development stage
- Preclinical
- Lead developer
- Augusta University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
gstm2-ps1 siRNA is a small interfering RNA (siRNA) designed to target and knock down the expression of the long non-coding RNA (lncRNA) gstm2-ps1 (the mouse homologue of human GSTM3P1). Developed by researchers at Augusta University, this siRNA is being investigated for its therapeutic potential in mitigating ischemic acute kidney injury (AKI). The lncRNA gstm2-ps1 is induced during renal ischemia-reperfusion injury and promotes proximal tubular cell apoptosis by binding to and inducing the degradation of the protective microRNA mir-668 via target-directed microRNA degradation (TDMD). In preclinical models, treatment with gstm2-ps1 siRNA significantly reduces renal tubular necrosis, apoptosis, and kidney injury biomarkers (such as NGAL), thereby protecting against ischemic AKI.
- Other names
- GSTM2-PS1 siRNAGSTM-2-PS1 siRNAGSTM 2-PS1 siRNAgstm2-ps1 siRNAsgstm-2-ps1 siRNAsgstm 2-ps1 siRNAs
Beyond the preview
Go deeper on gstm2-ps1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gstm2-ps1 siRNA.